Floatz logo

Epirubicin

Kaposi Sarcoma

Memorial Sloan Kettering Cancer CenterPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Kaposi Sarcoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Cyclophosphamide
Essen Biotech
Phase 1/2B
L19IL2/L19TNF
Philogen S.p.A.
Phase 2CCC
Pembrolizumab
Memorial Sloan Kettering Cancer Center
Phase 1CC
abc294640
RedHill Biopharma Limited
Phase 1/2CC

View all 9 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →